Boehringer Ingelheim International Gmbh

Biogen Swiss Manufacturing Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Bernd Wilhelm Mueller

Michael Trunk

Henrik Nilsson

Hartwig Andreas Steckel

Inga-Lis Timmermann

The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

Controlled release pharmaceutical compositions comprising a fumaric acid ester

The invention relates to a new process for preparing modified lactose mixtures, these lactose mixtures per se and compositions of medicaments for powder inhalation consisting of one or more micronised active substances and the modified lactose according to the invention.

Powdered inhalants based on modified lactose mixtures as excipient

The invention relates to a process for the surface-energy passivation of lactose which is intended for use as an excipient in the production of inhalable powders, and the use of such optimised carrier materials in the manufacture of inhalable powders.

Growing community of inventors

Flintbek, Germany

Bernd Wilhelm Mueller